Stocks/TSX/BLCO

Bausch + Lomb Corp (BLCO : TSX)

Common Stock

$20.60

CAD

-0.69 (-3.24%)

Last updated: 2026-06-02

BLCO

Bausch + Lomb Corp

Source:WealthAwesomeWealthAwesome
โ†“ $1.38 (-6.28%)
30 day period
$20.60$21.45$22.30Apr 21May 12Jun 2

Performance

1 Day

-3.24%

1 Week

-5.55%

1 Month

-6.53%

YTD

-9.61%

Key Statistics

Market Cap

$7.46B

52W High

$25.70

52W Low

$15.64

P/E Ratio

-

50 Day MA

$22.08

200 Day MA

$22.22

Beta

0.59

Dividend Yield

-

Technical Indicators

Price vs 50-Day SMA

โ†“Below 50 SMA

Price vs 200-Day SMA

โ†“Below 200 SMA

Recent Price History

DateOpenHighLowCloseAdj CloseVolume
6/2/2026$21.10$21.15$20.60$20.60$20.602,528
6/1/2026$21.48$21.48$21.11$21.29$21.291,726
5/29/2026$21.63$21.63$21.43$21.62$21.621,019
5/28/2026$21.55$21.62$21.50$21.55$21.552,509
5/27/2026$21.90$21.90$21.66$21.66$21.661,061
5/26/2026$22.18$22.18$21.69$21.81$21.811,741
5/25/2026$22.35$22.35$21.95$21.95$21.95611
5/22/2026$22.36$22.36$21.96$21.96$21.96600
5/21/2026$22.06$22.42$22.06$22.23$22.231,900
5/20/2026$22.08$22.30$22.08$22.21$22.211,607

Analyst Price Targets

Based on analyst covering BLCO

๐Ÿ“ˆ

Wall Street analysts forecast BLCO stock price to rise 25.8% over the next 12 months.

Consensus

No Rating

Avg. Target

C$25.92

+25.8% Upside

Current Price

C$20.60

Last close

Analyst ratings and price targets are updated periodically. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on BLCO's historical volatility

HistoricalForecast68%95%
C$12.45C$15.19C$17.94C$20.68C$23.43C$26.17TodayJan 23Mar 30Jun 2Jul 15Aug 28Oct 10

30-Day Vol

24.7%

Annualized

90-Day Vol

31.2%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$17.23

Expected price

HorizonExpected68% Range (1ฯƒ)
30 trading daysC$19.41C$17.83 โ€“ C$21.13
60 trading daysC$18.29C$16.21 โ€“ C$20.63
90 trading daysC$17.23C$14.87 โ€“ C$19.97

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯƒ, 95% band = ยฑ2ฯƒ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

About Bausch + Lomb Corp

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Financials

Revenue (TTM)
$5.21B
EBITDA
$724.00M
Profit Margin
-4.21%
ROE (TTM)
-3.28%
EPS (Diluted)
-0.86
Book Value
24.71

Classification

Sector
Health Care
Industry
Health Care Equipment & Supplies
Group
Health Care Equipment & Services

Advertisement

7 stocks to buy and hold forever

Blue-chip dividend stocks for long-term wealth building.

Get the FREE Report

Common Questions About BLCO

Advertisement